In patients without cancer but with a history of premalignant lesions (advanced colonic adenomas), a vaccine based on the tumor-associated antigen MUC1 was 30 to 40 times more immunogenic than the same vaccine in previous trials in cancer [15]. The gene discussed is MUC1; the disease is cancer.